TNF Inhibitors: Patient Selection
December 17, 2018 – 
Important factors that influence the decision to treat patients with autoimmune diseases with tumor necrosis factor (TNF) inhibitors.
Biologics and Small Molecules for Autoimmune Diseases
December 17, 2018 – 
Insight from Marla Dubinsky, MD, on historical approvals of biologic therapies and small molecule agents that expand the therapeutic landscape for patients with autoimmune diseases.
Steroid-Sparing Therapies for Autoimmune Disease
December 12, 2018 – 
Rationale for controlling autoimmune disorder inflammation with steroid-sparing therapies such as immunomodulators and biologics.
Nonbiologic Therapy for Autoimmune Diseases
December 12, 2018 – 
Clinical expertise on the use of corticosteroids and mesalamine-based products in the management of autoimmune diseases.
Accurately Diagnosing an Autoimmune Disease
December 06, 2018 – 
Criteria and the significance of biomarkers to help healthcare professionals avoid a misdiagnosis of an autoimmune disorder, such as an inflammatory bowel disease.
Factors and Exposures Linked to Autoimmune Diseases
December 06, 2018 – 
Risk factors that increase one’s likelihood for developing an autoimmune condition.
Distinguishing Between Autoimmune Conditions: IBD
November 26, 2018 – 
Common symptoms that help healthcare professionals distinguish between autoimmune diseases, such as inflammatory bowel diseases, and their impact on a patient’s quality of life.
Pathophysiology of Autoimmune Diseases and Inflammation
November 26, 2018 – 
Marla Dubinsky, MD, explains what is known about the pathophysiology of autoimmune diseases, such as inflammatory bowel disease.
Addressing Unmet Needs in Multiple Myeloma
October 09, 2018 – 
Amrita Krishnan, MD, FACP, considers the greatest unmet needs in the treatment of multiple myeloma and discusses the efforts being undertaken to address them.
Second Myeloma Relapse and Beyond: Upcoming Strategies
October 02, 2018 – 
Amrita Krishnan, MD, FACP, reflects on the potential role of novel therapies and strategies, such as immuno-oncology or targeted agents, at the second relapse of multiple myeloma and beyond.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.

Sign In

Not a member? Sign up now!